<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="935">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892657</url>
  </required_header>
  <id_info>
    <org_study_id>GLI.04.SRE.US10093</org_study_id>
    <nct_id>NCT01892657</nct_id>
  </id_info>
  <brief_title>Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test</brief_title>
  <official_title>Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examined the possible sensitization and irritation effects of a moisturizer with
      sunscreen SPF 50+.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design for this study is standard for human repeat insult patch tests. To test the
      moisturizer with sunscreen SPF 50+ for the potential to induce contact sensitization by
      repetitive applications, healthy subjects received 9 applications at 48 to 72 hour intervals
      of the moisturizer to the upper back. Patches were remained on the skin for approximately 48
      to 72 hours. Twelve to 24 days after the previous applications, subjects were patched with
      the moisturizer at the original site and an alternative site for 48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Area of Erythema and Elevated Responses of Skin to Product</measure>
    <time_frame>3 consecutive weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects were patched 9 times at 48 hour to 72 hour intervals and graded for erythema and elevated responses (edema, papules, vesicles, bullae) on a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). 12 to 24 hours after the last patch application, a challenge patch was applied at the same site and a challenge patch was applied to an alternate site. Both were graded for the same criteria at 48 hours and at 96 hours. A total of 11 patches were applied to each subject. All patches were removed after 48 hours.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Skin Irritation</condition>
  <arm_group>
    <arm_group_label>Facial Moisturizer with SPF 50+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Facial Moisturizer with SPF 50+</intervention_name>
    <description>All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+</description>
    <arm_group_label>Facial Moisturizer with SPF 50+</arm_group_label>
    <other_name>Cetaphil Daily Facial Moisturizer with SPF 50+</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 18 to 70 years of age in general good health

          -  Can read, understand, and sign informed consent

        Exclusion Criteria:

          -  History of acute or chronic disease

          -  Diagnosed with chronic skin allergies

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas J. Stephens and Associates, Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <lastchanged_date>July 23, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <firstreceived_results_date>July 23, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cetaphil Daily Facial Moisturizer with SPF 50+</keyword>
  <keyword>Hypoallergenicity</keyword>
  <keyword>Skin Irritation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened at a single US center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Facial Moisturizer With SPF 50+</title>
          <description>All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who were enrolled in the study and participated in all scheduled visits during the study were analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>Facial Moisturizer With SPF 50+</title>
          <description>All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="110"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.0" spread="13.68"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian/Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="110"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area of Erythema and Elevated Responses of Skin to Product</title>
        <description>Subjects were patched 9 times at 48 hour to 72 hour intervals and graded for erythema and elevated responses (edema, papules, vesicles, bullae) on a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). 12 to 24 hours after the last patch application, a challenge patch was applied at the same site and a challenge patch was applied to an alternate site. Both were graded for the same criteria at 48 hours and at 96 hours. A total of 11 patches were applied to each subject. All patches were removed after 48 hours.</description>
        <time_frame>3 consecutive weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Patch 1</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O2">
            <title>Patch 2</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O3">
            <title>Patch 3</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O4">
            <title>Patch 4</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O5">
            <title>Patch 5</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O6">
            <title>Patch 6</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O7">
            <title>Patch 7</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O8">
            <title>Patch 8</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O9">
            <title>Patch 9</title>
            <description>Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+</description>
          </group>
          <group group_id="O10">
            <title>Challenge Patch (Original Site) - 48 Hours</title>
            <description>The challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to the original application site was graded at 48 hours.</description>
          </group>
          <group group_id="O11">
            <title>Challenge Patch (Original Site) - 96 Hours</title>
            <description>The challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to the original application site was graded again at 96 hours.</description>
          </group>
          <group group_id="O12">
            <title>Challenge Patch (Alternate Site) - 48 Hours</title>
            <description>A challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to an alternate application site was graded at 48 hours.</description>
          </group>
          <group group_id="O13">
            <title>Challenge Patch (Alternate Site) - 96 Hours</title>
            <description>A challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to an alternate application site was graded again at 96 hours.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="110"/>
                  <measurement group_id="O3" value="110"/>
                  <measurement group_id="O4" value="110"/>
                  <measurement group_id="O5" value="110"/>
                  <measurement group_id="O6" value="110"/>
                  <measurement group_id="O7" value="110"/>
                  <measurement group_id="O8" value="110"/>
                  <measurement group_id="O9" value="110"/>
                  <measurement group_id="O10" value="110"/>
                  <measurement group_id="O11" value="110"/>
                  <measurement group_id="O12" value="110"/>
                  <measurement group_id="O13" value="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area of Erythema and Elevated Responses of Skin to Product</title>
            <description>Subjects were patched 9 times at 48 hour to 72 hour intervals and graded for erythema and elevated responses (edema, papules, vesicles, bullae) on a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). 12 to 24 hours after the last patch application, a challenge patch was applied at the same site and a challenge patch was applied to an alternate site. Both were graded for the same criteria at 48 hours and at 96 hours. A total of 11 patches were applied to each subject. All patches were removed after 48 hours.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="42"/>
                  <measurement group_id="O5" value="39"/>
                  <measurement group_id="O6" value="20"/>
                  <measurement group_id="O7" value="33"/>
                  <measurement group_id="O8" value="33"/>
                  <measurement group_id="O9" value="23"/>
                  <measurement group_id="O10" value="78"/>
                  <measurement group_id="O11" value="85"/>
                  <measurement group_id="O12" value="86"/>
                  <measurement group_id="O13" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="41"/>
                  <measurement group_id="O3" value="72"/>
                  <measurement group_id="O4" value="68"/>
                  <measurement group_id="O5" value="69"/>
                  <measurement group_id="O6" value="82"/>
                  <measurement group_id="O7" value="72"/>
                  <measurement group_id="O8" value="72"/>
                  <measurement group_id="O9" value="78"/>
                  <measurement group_id="O10" value="31"/>
                  <measurement group_id="O11" value="24"/>
                  <measurement group_id="O12" value="23"/>
                  <measurement group_id="O13" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="2"/>
                  <measurement group_id="O6" value="8"/>
                  <measurement group_id="O7" value="5"/>
                  <measurement group_id="O8" value="5"/>
                  <measurement group_id="O9" value="9"/>
                  <measurement group_id="O10" value="1"/>
                  <measurement group_id="O11" value="1"/>
                  <measurement group_id="O12" value="1"/>
                  <measurement group_id="O13" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Facial Moisturizer With SPF 50+</title>
          <description>All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth M. Nieman, Medical Information Specialist</name_or_title>
      <organization>Galderma Laboratories, L.P.</organization>
      <phone>817-961-5130</phone>
      <email>elizabeth.nieman@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
